{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:47:05Z","timestamp":1761896825197,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.atherosclerosis.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T20:23:47Z","timestamp":1531254227000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials"],"prefix":"10.1016","volume":"277","author":[{"given":"Dean J.","family":"Kereiakes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman E.","family":"Lepor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Veronica Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Elassal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Michael Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib2","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib3","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Committee","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib5","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib6","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib7","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib11","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National Lipid Association annual summary of clinical lipidology 2016","volume":"10","author":"Bays","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib15","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of alirocumab on lipoprotein(a) over >\/=1.5 years (from the Phase 3 ODYSSEY program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib17","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/01.CIR.0000140721.27004.4B","article-title":"Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials","volume":"110","author":"Cutlip","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jcin.2009.03.013","article-title":"Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting","volume":"2","author":"Chacko","year":"2009","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib19","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14779072.2018.1474099","article-title":"Role of proprotein convertase subtilisin\/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"16","author":"Navarese","year":"2018","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib25","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: pre-specified secondary end points in ORION 1","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib29","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","article-title":"Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials","volume":"118","author":"Jones","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib30","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","article-title":"Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials","volume":"223","author":"Farnier","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jacl.2016.12.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Kastelein","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/dme.13450","article-title":"Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials","volume":"35","author":"Leiter","year":"2018","journal-title":"Diabet. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.010_bib33","series-title":"Presented at the 67th Annual Scientific Session of the American College of Cardiology (ACC), 10\u201312 March 2018 (Presentation Number 401-08). Orlando, FL, USA","article-title":"Cardiovascular outcomes with alirocumab after acute coronary syndrome: results of the ODYSSEY outcomes trial","author":"Schwartz","year":"2018"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018312061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018312061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T17:41:38Z","timestamp":1565286098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018312061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":33,"alternative-id":["S0021915018312061"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.07.010","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}